• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一个新的 m6A 甲基化相关基因标志物，用于预测膀胱癌患者的预后。

A new m6A methylation-related gene signature for prognostic value in patient with urothelial carcinoma of the bladder.

机构信息

Cheeloo College of Medicine, Shandong University, Jinan, Shandong, P.R. China.

Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, P.R. China.

出版信息

Biosci Rep. 2021 Apr 30;41(4). doi: 10.1042/BSR20204456.

DOI:10.1042/BSR20204456
PMID:33779704
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8035626/
Abstract

BACKGROUND

Bladder cancer (BC) is one of the most common malignant urological cancer in the world. Because of its characteristic of easy-recurrence and muscle-invasive, advances in our genetic understanding of bladder cancer should be translated into prognostic indicators.

METHODS

We investigated 16 m6A RNA methylation regulators from The Cancer Genome Atlas (TCGA) database and The Human Protein Atlas (HPA) database. The expression profile, clinical application as well as prognostic value of these genes in UC were investigated. Moreover, we further explored the correlation between RNA methylation genes and biological functions, pathways and immune status.

RESULTS

Five m6A-related genes (HNRNPC, YTHDF2, YTHDF1, HNRNPA2B1, METTL3) up-regulated in UC tissues, while three regulators (ZC3H13, METTL16, FTO) down-regulated in UC. FTO and YTHDF2 show biomarker potential for the prognosis of UC patients. In addition, these identified genes may related with essential functions and core molecular pathways.

CONCLUSIONS

Our research shows that two m6A RNA methylation regulators can serve as reliable prognostic biomarkers of UC, which might be exerted as potential targets of therapeutic strategies.

摘要

背景

膀胱癌（BC）是世界上最常见的恶性泌尿系统癌症之一。由于其易复发和肌肉浸润的特点，我们对膀胱癌的遗传理解的进展应该转化为预后指标。

方法

我们从癌症基因组图谱（TCGA）数据库和人类蛋白质图谱（HPA）数据库中研究了 16 个 m6A RNA 甲基化调节剂。研究了这些基因在 UC 中的表达谱、临床应用和预后价值。此外，我们还进一步探讨了 RNA 甲基化基因与生物学功能、途径和免疫状态的相关性。

结果

在 UC 组织中上调了五个 m6A 相关基因（HNRNPC、YTHDF2、YTHDF1、HNRNPA2B1、METTL3），而在 UC 中下调了三个调节剂（ZC3H13、METTL16、FTO）。FTO 和 YTHDF2 显示出对 UC 患者预后的潜在生物标志物特征。此外，这些鉴定的基因可能与基本功能和核心分子途径有关。

结论

我们的研究表明，两种 m6A RNA 甲基化调节剂可以作为 UC 的可靠预后生物标志物，它们可能作为治疗策略的潜在靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e3/8035626/845dc2fd3bb4/bsr-41-bsr20204456-g7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e3/8035626/975d6700a6f8/bsr-41-bsr20204456-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e3/8035626/aea49fe3c0ed/bsr-41-bsr20204456-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e3/8035626/3b51ee23e960/bsr-41-bsr20204456-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e3/8035626/9761e671966a/bsr-41-bsr20204456-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e3/8035626/4fb5a17f4e95/bsr-41-bsr20204456-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e3/8035626/b7daedd50374/bsr-41-bsr20204456-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e3/8035626/845dc2fd3bb4/bsr-41-bsr20204456-g7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e3/8035626/975d6700a6f8/bsr-41-bsr20204456-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e3/8035626/aea49fe3c0ed/bsr-41-bsr20204456-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e3/8035626/3b51ee23e960/bsr-41-bsr20204456-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e3/8035626/9761e671966a/bsr-41-bsr20204456-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e3/8035626/4fb5a17f4e95/bsr-41-bsr20204456-g5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e3/8035626/b7daedd50374/bsr-41-bsr20204456-g6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b3e3/8035626/845dc2fd3bb4/bsr-41-bsr20204456-g7.jpg

相似文献

1
A new m6A methylation-related gene signature for prognostic value in patient with urothelial carcinoma of the bladder.一个新的 m6A 甲基化相关基因标志物，用于预测膀胱癌患者的预后。
Biosci Rep. 2021 Apr 30;41(4). doi: 10.1042/BSR20204456.
2
mA RNA methylation regulators have prognostic value in papillary thyroid carcinoma.m⁶A RNA 甲基化调控因子在甲状腺乳头状癌中有预后价值。
Am J Otolaryngol. 2020 Jul-Aug;41(4):102547. doi: 10.1016/j.amjoto.2020.102547. Epub 2020 May 17.
3
Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.m6A RNA 甲基化调控因子在肾上腺皮质癌进展和预后中的作用的生物信息学分析和实验验证。
Aging (Albany NY). 2021 Apr 21;13(8):11919-11941. doi: 10.18632/aging.202896.
4
Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.食管鳞癌中 PD-L1 表达、免疫浸润与 m6A RNA 甲基化调控因子的综合分析
Front Immunol. 2021 May 12;12:669750. doi: 10.3389/fimmu.2021.669750. eCollection 2021.
5
The Prognostic Value of m6A RNA Methylation Regulators in Colon Adenocarcinoma.m6A RNA 甲基化调控因子在结肠腺癌中的预后价值。
Med Sci Monit. 2019 Dec 11;25:9435-9445. doi: 10.12659/MSM.920381.
6
Expression patterns and prognostic value of m6A RNA methylation regulators in adrenocortical carcinoma.m6A RNA 甲基化调节剂在肾上腺皮质癌中的表达模式及预后价值。
Medicine (Baltimore). 2021 Mar 12;100(10):e25031. doi: 10.1097/MD.0000000000025031.
7
Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer.全面描绘肿瘤微环境和 m6A RNA 甲基化调控因子，并研究其对宫颈癌 PD-L1 和免疫浸润的影响。
Front Immunol. 2022 Aug 26;13:976107. doi: 10.3389/fimmu.2022.976107. eCollection 2022.
8
Identification of a Two-m6A RNA Methylation Regulator Risk Signature as an Independent Prognostic Biomarker in Papillary Renal Cell Carcinoma by Bioinformatic Analysis.基于生物信息学分析鉴定出的两个 m6A RNA 甲基化调控因子风险签名作为乳头状肾细胞癌的独立预后生物标志物。
Biomed Res Int. 2021 Feb 6;2021:4582082. doi: 10.1155/2021/4582082. eCollection 2021.
9
Comprehensive analysis of m6A related gene mutation characteristics and prognosis in colorectal cancer.综合分析结直肠癌 m6A 相关基因突变特征与预后。
BMC Med Genomics. 2023 May 16;16(1):105. doi: 10.1186/s12920-023-01509-8.
10
m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer.m6A RNA 甲基化调控因子可促进膀胱癌的恶性进展并影响其预后。
Biosci Rep. 2019 Dec 20;39(12). doi: 10.1042/BSR20192892.

引用本文的文献

1
The impact of METTL3 on bladder cancer through mA modification: a potential therapeutic target and prognostic biomarker.METTL3通过m⁶A修饰对膀胱癌的影响：一个潜在的治疗靶点和预后生物标志物。
Front Oncol. 2025 Jul 3;15:1622117. doi: 10.3389/fonc.2025.1622117. eCollection 2025.
2
ZC3H13 promotes autophagy in bladder cancer through m6A methylation modification of PJA2 and ubiquitination of KSR1.ZC3H13 通过 PJA2 的 m6A 甲基化修饰和 KSR1 的泛素化促进膀胱癌中的自噬。
Hum Cell. 2024 Nov 30;38(1):23. doi: 10.1007/s13577-024-01155-x.
3
The identification of a N-methyladenosin-modifed immune pattern to predict immunotherapy response and survival in urothelial carcinoma.

本文引用的文献

1
FTO modifies the m6A level of MALAT and promotes bladder cancer progression.FTO 修饰 MALAT 的 m6A 水平并促进膀胱癌进展。
Clin Transl Med. 2021 Feb;11(2):e310. doi: 10.1002/ctm2.310.
2
Dysregulation of USP18/FTO/PYCR1 signaling network promotes bladder cancer development and progression.USP18/FTO/PYCR1 信号网络失调促进膀胱癌发生和进展。
Aging (Albany NY). 2021 Jan 10;13(3):3909-3925. doi: 10.18632/aging.202359.
3
Wnt signalling pathway in bladder cancer.膀胱癌中的 Wnt 信号通路。
鉴定 N6-甲基腺苷修饰的免疫模式，以预测尿路上皮癌的免疫治疗反应和生存。
Aging (Albany NY). 2024 May 1;16(9):7774-7798. doi: 10.18632/aging.205782.
4
Multi-omics comprehensive analysis reveals the predictive value of N6-methyladenosine- related genes in prognosis and immune escape of bladder cancer.多组学综合分析揭示 N6-甲基腺苷相关基因在膀胱癌预后和免疫逃逸中的预测价值。
Cancer Biomark. 2024;40(1):79-94. doi: 10.3233/CBM-230286.
5
METTL16 suppressed the proliferation and cisplatin-chemoresistance of bladder cancer by degrading PMEPA1 mRNA in a m6A manner through autophagy pathway.METTL16 通过自噬途径以 m6A 方式降解 PMEPA1 mRNA 抑制膀胱癌的增殖和顺铂化疗耐药性。
Int J Biol Sci. 2024 Feb 4;20(4):1471-1491. doi: 10.7150/ijbs.86719. eCollection 2024.
6
The epitranscriptome of high-grade gliomas: a promising therapeutic target with implications from the tumor microenvironment to endogenous retroviruses.高级别神经胶质瘤的表观转录组学：一个有前途的治疗靶点，涉及肿瘤微环境到内源性逆转录病毒。
J Transl Med. 2023 Dec 9;21(1):893. doi: 10.1186/s12967-023-04725-z.
7
METTL16 in human diseases: What should we do next?人类疾病中的METTL16：我们接下来该怎么做？
Open Med (Wars). 2023 Nov 30;18(1):20230856. doi: 10.1515/med-2023-0856. eCollection 2023.
8
Reinvestigating the clinical relevance of the mA writer METTL3 in urothelial carcinoma of the bladder.重新研究膀胱尿路上皮癌中mA书写器METTL3的临床相关性。
iScience. 2023 Jul 11;26(8):107300. doi: 10.1016/j.isci.2023.107300. eCollection 2023 Aug 18.
9
RNA Methyltransferase METTL16's Protein Domains Have Differential Functional Effects on Cell Processes.RNA甲基转移酶METTL16的蛋白结构域对细胞过程具有不同的功能影响。
Curr Issues Mol Biol. 2023 Jun 29;45(7):5460-5480. doi: 10.3390/cimb45070346.
10
The emerging roles and mechanism of N6-methyladenosine (mA) modifications in urologic tumours progression.N6-甲基腺苷（m⁶A）修饰在泌尿系统肿瘤进展中的新作用及机制
Front Pharmacol. 2023 May 22;14:1192495. doi: 10.3389/fphar.2023.1192495. eCollection 2023.
Cell Signal. 2021 Mar;79:109886. doi: 10.1016/j.cellsig.2020.109886. Epub 2020 Dec 17.
4
Control of Early B Cell Development by the RNA N-Methyladenosine Methylation.RNA N6-甲基腺苷甲基化调控早期 B 细胞发育
Cell Rep. 2020 Jun 30;31(13):107819. doi: 10.1016/j.celrep.2020.107819.
5
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion.靶向 FTO 抑制癌症干细胞维持和免疫逃逸。
Cancer Cell. 2020 Jul 13;38(1):79-96.e11. doi: 10.1016/j.ccell.2020.04.017. Epub 2020 Jun 11.
6
Limits in the detection of mA changes using MeRIP/mA-seq.使用 MeRIP/mA-seq 检测 mA 变化的局限性。
Sci Rep. 2020 Apr 20;10(1):6590. doi: 10.1038/s41598-020-63355-3.
7
Down-regulation of FTO promotes proliferation and migration, and protects bladder cancer cells from cisplatin-induced cytotoxicity.下调 FTO 可促进膀胱癌增殖和迁移，并保护膀胱癌细胞免受顺铂诱导的细胞毒性。
BMC Urol. 2020 Apr 16;20(1):39. doi: 10.1186/s12894-020-00612-7.
8
METTL3/YTHDF2 m A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer.METTL3/YTHDF2 mA 轴通过降解膀胱癌中的 SETD7 和 KLF4 mRNA 促进肿瘤发生。
J Cell Mol Med. 2020 Apr;24(7):4092-4104. doi: 10.1111/jcmm.15063. Epub 2020 Mar 3.
9
N6-methyladenosine demethylase FTO promotes M1 and M2 macrophage activation.N6-甲基腺嘌呤去甲基酶 FTO 促进 M1 和 M2 巨噬细胞的激活。
Cell Signal. 2020 May;69:109553. doi: 10.1016/j.cellsig.2020.109553. Epub 2020 Feb 1.
10
Epigenetic Regulation of mA Modifications in Human Cancer.人类癌症中 mA 修饰的表观遗传调控
Mol Ther Nucleic Acids. 2020 Mar 6;19:405-412. doi: 10.1016/j.omtn.2019.11.022. Epub 2019 Nov 29.